drugset
drugset / Trial / NCT01526603

High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

NCT01526603 ↗

Completed 13 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelOther

Summary

This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.

Timeline

Start
2012-03-28
Primary completion
2023-05-30
Completion
2023-05-30

Drugs

EvaluationDrugModalityDoseRoute
Background Carboplatin Small molecule 14.2 mg/kg Intravenous
Background Carboplatin Small molecule 425 mg/m2 Intravenous
Background Etoposide Small molecule 11.3 mg/kg Intravenous
Background Etoposide Small molecule 338 mg/m2 Intravenous
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 5 ug/kg Subcutaneous
Background Isotretinoin Other / unclassified 5.33 mg/kg —
Background Isotretinoin Other / unclassified 160 mg/m2 —
Background Melphalan Small molecule 2.3 mg/kg Intravenous
Background Melphalan Small molecule 70 mg/m2 Intravenous

Indications

neuroblastoma